Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer: A phase I study

H. Safran, T. P. King, H. Choy, P. J. Hesketh, B. Wolf, E. Altenhein, W. Sikov, A. Rosmarin, W. Akerley, K. Radie-Keane, G. Cicchetti, F. Lopez, K. Bland, H. J. Wanebo

Research output: Contribution to journalArticlepeer-review

79 Scopus citations

Abstract

Purpose: To determine the maximum-tolerated dose (MTD), dose-limiting toxicities, and potential antitumor activity of weekly paclitaxel with concurrent radiation (RT) for locally advanced pancreatic and gastric cancer. Patients and Methods: Thirty-four patients with locally advanced adenocarcinoma of the pancreas or stomach were studied. The initial dose of paclitaxel was 30 mg/m2 by 3-hour intravenous (IV) infusion repeated every week for 6 weeks with 50 Gy RT. Doses were escalated at 10-mg/m2 increments in successive cohorts of three new patients until dose-limiting toxicity was observed. Results: The dose-limiting toxicities at 60 mg/m2/wk were abdominal pain within the RT field, nausea, and anorexia. Of 23 patients with assessable disease, 11 (seven with gastric, four with pancreatic cancer) had objective responses for an overall response rate of 48%. Conclusion: Concurrent paclitaxel with upper abdominal RT is well tolerated at dosages that have substantial activity. A phase II trial of neoadjuvant paditaxel and RT at the MTD of 50 mg/m2/wk is underway.

Original languageEnglish (US)
Pages (from-to)901-907
Number of pages7
JournalJournal of Clinical Oncology
Volume15
Issue number3
DOIs
StatePublished - Mar 1997

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer: A phase I study'. Together they form a unique fingerprint.

Cite this